Communiqué from the Extraordinary General Meeting of Oncology Venture Sweden AB (publ)
Today, October 11, 2016, Oncology Venture Sweden AB (publ) held an Extraordinary General Meeting. Below is a summary of the decision taken. The decision was taken with the required majority.Approval of the Board of Directors’ decision concerning a preferential rights issue General Meeting decided to increase the company’s share capital, via a preferential rights issue, by a maximum of SEK 108,497.76 by means of the issuance of up to 774,984 new shares each with a par value of SEK 0.14, at a subscription price of SEK 29.00 per share. The total value of the shares to be issued amounts to